Literature DB >> 378352

A method for distinguishing benign from malignant breast lesions utilizing antibody present in normal human sera.

D R Howard, C R Taylor.   

Abstract

A sensitive immunoperoxidase technique was utilized 1) to detect the presence in normal human serum of antibody directed against breast carcinoma cells (tumor associated antibody--TAA) and 2) to determine whether this antibody could be used to discriminate between benign and malignant breast epithelium in sections of formalin fixed paraffin embedded tissue. A total of 16 benign and 13 malignant breast lesions were examined for evidence of binding of human immunoglobulin, before and after application of normal human AB serum containing the putative tumor associated antibody--TAA. Malignant cells showed significant binding of human immunoglobulin (TAA); benign or normal cells did not. Clear immunohistological separation of benign and malignant breast lesions appears possible by this method.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 378352     DOI: 10.1002/1097-0142(197906)43:6<2279::aid-cncr2820430618>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  A method for T-antigen demonstration by a polyclonal antibody and peanut lectin; elimination of cross-reaction with naturally occurring antibodies.

Authors:  T F Orntoft
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

2.  A spectrum of monoclonal antibodies reactive with human mammary tumor cells.

Authors:  D Colcher; P H Hand; M Nuti; J Schlom
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

3.  Generation of human monoclonal antibodies reactive with human mammary carcinoma cells.

Authors:  J Schlom; D Wunderlich; Y A Teramoto
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

4.  Biochemical and immunological characterizations of antigens recognised by human monoclonal antibodies.

Authors:  A Imam; C R Taylor
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.